Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Denali Therapeutics Inc shares valued at $125,541 were purchased by VICKI LEE SATO on Jan 02 ’25. At $20.38 per share, VICKI LEE SATO acquired 6,160 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, STEVE KROGNES purchased 30,000 shares, netting a total of over 607,200 in proceeds.
Before that, Schenkein David P had sold 59,441 shares from its account. In a trade valued at $1,932,665, the Director traded Denali Therapeutics Inc shares for $32.51 each. Upon closing the transaction, the insider’s holdings decreased to 59,441 shares, worth approximately $0.19 million.
As published in a research note from Stifel on December 16, 2024, Denali Therapeutics Inc [DNLI] has been rated up from a Hold to a Buy and the price target has been revised to $37. As of October 07, 2024, Cantor Fitzgerald has decreased its “an Overweight” rating to a “Neutral” for DNLI. Earlier on December 13, 2023, Citigroup initiated its rating. Their recommendation was “a Buy” for DNLI stock.
Analyzing DNLI Stock Performance
During the last five days, there has been a drop of approximately -0.38%. Over the course of the year, Denali Therapeutics Inc shares have jumped approximately 2.26%. Shares of the company reached a 52-week high of $21.18 on 01/02/25 and a 52-week low of $20.45 on 01/02/25. A 50-day SMA is recorded $24.97, while a 200-day SMA reached $23.09. Nevertheless, trading volume fell to 0.7 million shares from 0.6 million shares the previous day.
Support And Resistance Levels for Denali Therapeutics Inc (DNLI)
According to the 24-hour chart, there is a support level at 20.47, which, if violated, would cause prices to drop to 20.09. In the upper region, resistance lies at 21.20. The next price resistance is at 21.55. RSI (Relative Strength Index) is 35.14 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.11, which suggests the price will decrease in the coming days. Percent R is at 78.44%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
